Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INFOGRAPHIC: Mental Health; A Road Still Less Travelled By Pharma

Executive Summary

The scope of mental disorders and increasing patient numbers represent opportunity for pharma and biotech, but historically these conditions have carried high risk/low success rate labels. As the number of patients continues to grow with the world's expanding and aging population, voids in available drug treatments for some conditions will become more apparent.

You may also be interested in...



If Alkermes Antidepressant Can Get Past FDA, The Market Might Be There

Alkermes’s announcement of positive findings in the FORWARD-5 trial of its treatment-resistant depression drug ALKS 5461 came as a surprise, given the past two Phase III trials disappointed, but if it can gain approval, the buprenorphine/samidorphan product could meet an unmet need.

Surprise Failure for Intra-Cellular Therapies’ Schizophrenia Drug Sends Shares Tumbling

The unexpected failure of a Phase III trial of Intra-Cellular Therapies’ lead product ITI-007 sent shares in the company down by more than 63%.

Lundbeck's Alzheimer's Strategy Targets Symptoms And Disease Modification

The private company may be behind the leaders, but with a long-term plan and a strategy of coming in with complementary therapies like the 5-HT6 receptor antagonist idalopirdine and the dopamine antagonist Rexulti (brexpiprazole), it could be a stable player in Alzheimer's.

Related Content

Topics

UsernamePublicRestriction

Register

SC097536

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel